Using IGF1 as a marker of adequacy of GH replacement is therefore problematic; one approach is to titrate the GH dose to an IGF1 between the age-related median and the upper limit of normal, but in T1DM this is not possible as was evident in this patient. The gene discussed is IGF1; the disease is type 1 diabetes mellitus.